Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial

Autor:	A Murias, Amparo Ruiz, Y. Ye, Arlene Chan, Anne C Armstrong, Michael Gnant, Robert Šeparović, Julie Means-Powell, Rina Hui, Hiroji Iwata, Joanne Chiu, Anna Bashford, Ingrid A. Mayer, Francis M. Senecal, Richard A. Bryce, Richard De Boer, Elena Vicente
Rok vydání:	2018
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry medicine.disease Breast cancer Trastuzumab Internal medicine Neratinib medicine Adjuvant therapy Duration (project management) Stage (cooking) business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:524-524
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.524
Popis:	524Background: The optimal duration of adjuvant therapy with targeted agents remains a question of ongoing relevance in oncology. ExteNET, an international, randomized, placebo-controlled phase III...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1ef7c544012e330d244f06d195563d81 https://doi.org/10.1200/jco.2018.36.15_suppl.524 Zobrazit plný text záznamu